Completion of Pharma Intelligence divestment

RNS Number : 4796N

Informa PLC

01 June 2022

 

Informa PLC Press Release

1 June 2022

Completion of £1.9bn Pharma Intelligence agreement

Portfolio re-balancing and accelerating shareholder returns

Informa (LSE: INF.L), the international Academic Markets, B2B Markets and Digital Services Group today confirmed the completion of its £1.9bn Pharma Intelligence agreement which forms part of the 2021-2024 Growth Acceleration Plan II ("GAP II").

The agreement announced on 10 February sees the Group receive c.£1.7bn in cash before tax deductions and a c.15% shareholding in the ongoing business. This c.15% equity interest ranks pari passu with Warburg Pincus' equity (the acquirer), enabling Informa to realise significant value today, whilst sharing in the future value created from further growth and portfolio expansion.

Re-balancing the Group's portfolio is a key part of Informa's GAP II programme, a four-year plan designed to create a more focused, higher growth business, with digital and data excellence at its core. Following Pharma Intelligence, the Group is now reviewing its Financial Intelligence portfolio.

The Group will provide an update on GAP II Shareholder Returns within its AGM Trading Update on 16 June 2022. Since March, the Group has completed c.£257m of its current £300m share buyback commitment, at a weighted average price of 581p, leading to the cancellation of c.44m shares.

Enquiries
Stephen A. Carter, Chief Executive	[phone]
Gareth Wright, Finance Director	[phone]
Richard Menzies-Gow, Director of IR & Communications	[phone]
Tim Burt / Simon Duke - Teneo	[phone]

 

END

 

 

DISBFLLXLELBBBF